Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Moshen Digui (MSDG) is a traditional Chinese medicine (TCM) compound formula that has been widely used in China for the treatment of idiopathic membranous nephropathy (IMN), a common cause of nephrotic syndrome in nondiabetic adults. The formula is considered an empirical TCM prescription and is typically administered as part of integrative therapy for IMN. Clinical practice and retrospective data suggest that MSDG can significantly reduce proteinuria and delay disease progression in IMN patients. While its efficacy and safety have been observed clinically, high-quality randomized controlled trials are still lacking. In recent studies, ultrasonic infiltration—a novel drug delivery method—has been explored to improve patient compliance compared to traditional oral administration due to the poor taste of some TCMs[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Moshen Digui.